Lineage Cell Therapeutics, Inc.

Total revenues were $1.1 million, down $1.7 million from $2.8 million in the same period of 2025. Total operating expenses were $10 million, down $12.5 million from $22.5 million in the prior-year quarter, mainly because the prior year included a $14.8 million noncash impairment charge. R&D expense was $4.8 million versus $3.1 million a year ago, and G&A expense was $5.2 million versus approximately $4.5 million. Loss from operations was $8.9 million versus $19.8 million a year ago. Other income was $10.5 million versus other expense of $10.6 million last year, driven largely by the quarterly fair value remeasurement of warrant liabilities. Net income attributable to Lineage was $1.5 million, or $0.01 per basic share and a $0.03 loss per diluted share, versus a net loss of $30.5 million, or $0.13 per share, in Q2 2025. As of June 30, 2026, cash, cash equivalents and marketable securities were $50.8 million, expected to fund operations into Q3 2028. Management said it raised approximately $4.6 million on June 26 at a weighted average price of $1.28 per share. They also cited approximately $32 million of potential warrant proceeds, up to $615 million of potential Roche milestone payments, and additional partnership opportunities. No quarterly revenue or EPS guidance was provided.

Brian Culley framed the quarter around what he called Lineage 3.0: using the AlloSCOPE platform to generate a broader, more internally owned pipeline rather than relying solely on OpRegen. He repeatedly stressed manufacturing as the core competitive advantage, arguing that Lineage is building programs with scalable, controlled production from the start. His tone was confident and explanatory, with a strong emphasis on the difficulty of cell-therapy manufacturing and the value of proving scale early.

Jill Howe focused on the balance sheet and the quarter’s accounting-driven results. She said the company had $50.8 million in cash, cash equivalents and marketable securities and expects that to fund operations into Q3 2028, helped by the $4.6 million ATM sale on Russell Reconstitution Day at a $1.28 weighted average price. She also cited approximately $32 million of potential warrant proceeds, up to $615 million of Roche milestone payments, and described the quarter’s net income as being largely driven by a noncash gain from warrant-liability remeasurement plus foreign exchange effects. Operating discipline and prudent capital allocation were highlighted as ongoing priorities.

Analysts focused on the diabetes and spinal cord injury programs, COR1 timing, and OpRegen milestones and rights. Management declined to disclose the specific multiliter scale for the diabetes program, saying they want to protect the platform’s know-how, but said the work had progressed to a larger multi-tier format and that more updates are likely before year-end. On DOSED, management said the first four patients each require a one-month DSMB break, the third patient is being assessed, all current candidates are chronic patients, and the goal is to complete remaining patients within roughly 12 months. On OpRegen, Brian Culley reiterated the $615 million in potential development and commercial milestones, said the company has a double-digit royalty structure rather than co-promote rights, and explained that the EMA IRIS registration was an administrative step, not a commitment by Roche or Genentech to proceed in Europe.